In glioma and sarcoma models, CAR T cells engineered with Zip18R displayed significantly greater antitumor efficacy than unmodified CAR T cells, with enhanced persistence and elevated secretion of effector cytokines such as IFN-γ, IL-2, and TNF-α. This evidence concerns the gene TNF and glioma.